Sirtex Medical Limited (ASX: SRX) today announced dose sales of its SIR-Spheres® microspheres targeted radiation therapy for liver cancer grew 27.1 per cent for the quarter ended 30th June 2014 compared to the previous corresponding period.
Dose sales during the fourth quarter, compared to the same period last year, grew in all regions. The Americas achieved dose sales growth of 33.0 per cent, EMEA (Europe, Middle East and Africa) achieved growth of 16.7 per cent, and APAC (Asia Pacific) achieved growth of 11.7 per cent. Sirtex has now reported 40 consecutive quarters of dose sales growth.
Dose sales have been a key measure of the company’s business performance.
Sirtex Chief Executive Officer, Gilman Wong said, “This is a significant milestone. Sirtex has now achieved the impressive record of 10 years of consistent quarterly growth and we expect this trend will continue. Sirtex’s focus is on achieving its 2020Vision with the aim to deliver an acceleration in growth in the medium to longer term. We will in future no longer report quarterly dose sales results however we will be reporting on key elements of our 2020Vision strategy.
The successful implementation of our 2020Vision strategy with appropriate investment by the company in sales and marketing, manufacturing, clinical studies and research should ensure Sirtex achieves its future potential.”
For full access, please click here.
Help employers find you! Check out all the jobs and post your resume.
